OCTA Changes in Choroidal Neovascularization in High Myopia

Optical Coherence Tomography Angiography Changes in Choroidal Neovascularization in High Myopia

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06357559

Enrollment

100

Registered

2024-04-10

Start date

2024-04-30

Completion date

2024-12-01

Last updated

2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopic Choroidal Neovascularisation

Brief summary

To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV..

Detailed description

To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV.. regarding the size , shape , core , margin , Appearance , and activity of CNV..

Interventions

DEVICEOCTA

Optical Coherence Tomography Angiography

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

10 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* All Patients with High Myopia ( \> -6 D or Axial Length \> 26.5 mm ) with Fundoscopic Changes Consistent with CNVM , with Clear Media are Subjected to OCTA

Exclusion criteria

* Patients with Treated CNVs , or with other Causes of CNVs including : Neovascular AMD , Idiopathic CNV , Traumatic , Inflammatory , Neoplastic , Degenerative ..

Design outcomes

Primary

Measure	Time frame	Description
Describing the Choroidal Neovascularization in High Myopic Patients diagnosed by OCTA	1 year	Describing the Choroidal Neovascularization in High Myopic Patients diagnosed by OCTA Regarding its Activity ..

Contacts

Primary ContactAhmed Hamdy

fcb9976@Gmail.com01287307536

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026